Temporary MCS With the iVAC 2L Transaortic Device in High-risk PCI
Trial Information
Current as of September 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new temporary heart support device called the iVAC 2L, which is used during a procedure called high-risk percutaneous coronary intervention (PCI). PCI is a treatment that opens blocked heart arteries but can be risky for some patients, especially those with serious heart artery disease or heart failure. The iVAC 2L device helps support the heart by assisting blood flow during the procedure, aiming to keep the heart stable and improve both short- and long-term outcomes.
People who may be eligible for this study are adults between 65 and 74 years old who have significant coronary artery disease and are scheduled for a high-risk PCI. If you join, the device will be temporarily placed through an artery in your leg and positioned in the heart to help pump blood during the procedure. The study will follow participants to see how safe the device is and whether it reduces serious problems like heart attack, stroke, or death during the hospital stay and up to one year afterward. This trial is currently recruiting patients and includes both men and women who meet the criteria.
Gender
ALL
Eligibility criteria
About
No description available.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Dmitry Pevzner, MD
Principal Investigator
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Evgeniy Merkulov, MD
Principal Investigator
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported